Discontinued study drug due to adverse event or 7 (3%) 24 (10%) death, n (%) Discontinued study drug due to other reasons and 9 (4%) 13 (5%) last available HIV-1 RNA was < 50 copies/mL, n (%) Missing data during window but on study drug, n (%) 0 1 (0.4%) Table S2. Snapshot Analysis: Virologic Outcomes at Week 48 for Subjects with Baseline HIV-1 RNA >100,000 copies/mL RPV/FTC/TDF EFV/FTC/TDF (n = 394) (n = 392) P value Subjects with Baseline HIV-1 RNA >100,000 copies/mL 134 142 Virologic success at Week 48 HIV-1 RNA < 50 copies/mL, n (%) 107 (80%) 116 (82%) 0.70 Virologic failure at Week 48, (%) 19 (14%) 14 (10%) 0.27 n HIV-1 RNA 50 copies/mL, n (%) 4 (3%) 3 (2%) Discontinued study drug due to lack of efficacy, n (%) 11 (8%) 1 (0.7%) Discontinued study drug due to other reasons and last 4 (3%) 10 (7%) available HIV-1 RNA 50 copies/mL, n (%) No virologic data in Week 48 window, n (%) 8 (6%) 12 (13%) Discontinued study drug due to adverse event or 0 8 (6%) death, n (%)
Discontinued study drug due to adverse event or death, n (%) 7 (3%) 24 (10%) Discontinued study drug due to other reasons and last available HIV-1 RNA was < 50 copies/mL, n (%) 9 (4%) 13 (5%) Missing data during window but on study drug, n (%) 0 1 (0.4%) Table S2. Snapshot Analysis: Virologic Outcomes at Week 48 for Subjects with Baseline HIV-1 RNA >100,000 copies/mL RPV/FTC/TDF (n = 394) EFV/FTC/TDF (n = 392) P value Subjects with Baseline HIV-1 RNA >100,000 copies/mL Virologic success at Week 48 134 142 HIV-1 RNA < 50 copies/mL, n (%) 107 (80%) 116 (82%) 0.70 Virologic failure at Week 48, n (%) 19 (14%) 14 (10%) 0.27 HIV-1 RNA 50 copies/mL, n (%) 4 (3%) 3 (2%) Discontinued study drug due to lack of efficacy, n (%) 11 (8%) 1 (0.7%) Discontinued study drug due to other reasons and last available HIV-1 RNA 50 copies/mL, n (%) 4 (3%) 10 (7%) No virologic data in Week 48 window, n (%) 8 (6%) 12 (13%) Discontinued study drug due to adverse event or death, n (%) 0 8 (6%)
QAD_2014_01_04_COHEN_AIDS-D-13-00893_SDC1.docx